At the 2018 American Academy of Dermatology (AAD) Annual Meet
Glenmark Pharmaceuticals has presented findings from a Phase 2a study of GBR 830, an investigational anti-OX40 monoclonal antibody, at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego. The GBR 830 Phase 2a study was a double-blind, placebo-controlled study in adults with moderate-to-severe atopic dermatitis (AD) that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
